Perfuze is a technology company.
Perfuze has raised $53.0M across 3 funding rounds.
Perfuze has raised $53.0M in total across 3 funding rounds.
Perfuze is a medical technology company specializing in advanced catheter-based devices designed to treat acute ischemic stroke by removing blood clots from the brain. Their flagship products, including the Millipede 070 Aspiration Catheter and the Millipede 088 Access Catheter, leverage innovative superbore aspiration technology to simplify access and improve clot removal efficiency. Perfuze primarily serves hospitals and neurovascular specialists, addressing the critical need for faster, more effective mechanical thrombectomy procedures to improve patient outcomes in stroke care. The company has demonstrated strong growth momentum, securing over $28 million in funding and achieving FDA clearances for its devices, positioning itself as a significant player in the stroke treatment market[1][2][4].
Founded in 2018 and headquartered in Galway, Ireland, Perfuze was established by founders with over 30 years of combined experience in the medtech industry, spanning startups and large corporations. The idea emerged from the urgent clinical need to improve treatment for acute ischemic stroke, a leading cause of disability and death worldwide. Early traction came from regulatory milestones, including FDA breakthrough device designation and subsequent clearances, which validated their technology and accelerated market entry. The company’s evolution has focused on refining catheter design to enhance speed, safety, and ease of use in neurovascular interventions[1][3][5].
Perfuze operates at the intersection of medtech innovation and the growing demand for improved acute ischemic stroke interventions. The global rise in stroke incidence and increasing adoption of mechanical thrombectomy procedures create a favorable market environment. Advances in catheter technology, such as superbore aspiration, align with trends toward minimally invasive, rapid, and effective neurovascular treatments. The company’s innovations contribute to the broader ecosystem by potentially setting new standards for device performance and patient outcomes, influencing clinical practice and competitive dynamics in the stroke device market[1][2][4].
Looking ahead, Perfuze is poised to expand its market share in the US and global mechanical thrombectomy device markets by leveraging ongoing clinical trials and regulatory approvals. Trends such as aging populations, increased stroke awareness, and healthcare system investments in neurointerventional capabilities will shape their growth trajectory. Future innovations may include expanded device indications and integration with digital health tools for stroke care optimization. Perfuze’s continued focus on simplifying and improving stroke treatment positions it to be a key influencer in advancing neurovascular intervention standards and patient outcomes. Their journey reflects a critical mission to transform stroke care through technology innovation[2][5].
Perfuze has raised $53.0M in total across 3 funding rounds.
Perfuze's investors include Earlybird Venture Capital, EQT Life Sciences, Seroba Life Sciences.
Perfuze has raised $53.0M across 3 funding rounds. Most recently, it raised $24.0M Venture Round in March 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2025 | $24.0M Venture Round | Earlybird Venture Capital, EQT Life Sciences, Seroba Life Sciences | |
| Feb 1, 2022 | $26.0M Series A | Earlybird Venture Capital, EQT Life Sciences, Seroba Life Sciences | |
| Jan 1, 2019 | $3.0M Seed | Earlybird Venture Capital |